INTRODUCTION
Prostaglandins and related compounds play an important role in a number of pathophysiological proc- in some cases, opposing. Thus, thromboxane A2, which is synthesized by platelets and other cells induces platelet aggregation whereas PGI2, which is synthesized by vascular wall cells, inhibits platelet aggregation (1) . Aspirin has been shown to inhibit the release reaction by acetylating platelet cyclo-oxygenase and so inhibit the synthesis of prostaglandirns and thromboxane A2 (2) . This effect is achieved by a low concentration of aspirin and lasts for the life-span of the platelet. Aspirin also inhibits PGI2 synthesis by the vessel wall, an effect which could be potentially thrombogenic (3) . Recently, it has been reported that the concentration of aspirin required to inhibit PGI2 formation by cultured smooth muscle cells ofthe vessel wall is much higher than that required to inhibit prostaglandin synthesis by platelets (4), a finding which suggests that in the doses used clinically, aspirin may inhibit platelet prostaglandin synthesis without affecting PGI2 formation by the vessel wall.
To 30 min before the injury to the veins, the animals were infused with either a placebo (saline), sodium salicylate (pH 7.0), or aspirin dissolved in equimolar sodium carbonate buffer solution (pH 7.0). Less than 3% of the aspirin had hydrolyzed into sodium salicylate. 5 h after the initial vessel damage, the animals were injected with 1,000 U of heparin to prevent postmortem clotting and sacrificed with an overdose of sodium pentobarbital. The vein segments were then clamped above and below the site ofexperimental thrombosis, removed, opened lengthwise, and then washed in a petri dish of saline. The radioactivity of the thrombi, and plasma samples, was measured in a model 1085 Nuclear-Chicago gamma counter (Nuclear-Chicago Corp., De Plaines, Ill.). The amount of fibrinogen accreted into the thrombi was calculated by relating the 125I activity of the washed thrombi to the mean specific activity of the plasma fibrinogen during the experiment, as previously described (6) .
The effect of tranylcypromine (Smith Kline & French Laboratories, Philadelphia), an inhibitor of PGI2 synthesis (7), on injury-induced thrombosis was investigated in a similar manner. The jugular vein segments were temporarily occluded with sutures and emptied ofblood. One vein was filled with 7.5 mM tranylcyromine and the opposite side was filled with 0.5 ml sodium chloride (0.9%). After 10 min the sutures were released and blood flow restored. Experimental thrombosis was then induced as described. (Fig. 1) . The effects of varying the interval between the administration of aspirin and producing damage to the jugular veins is shown in Fig. 2 . A 200-mg/kg dose of aspirin potentiated thrombosis when it was administered ½2 h before injury. This thrombotic effect was lost if an interval of 2.5 or 4 h elapsed between drug administration and injury.
When tranylcypromine was administered in doses which were large enough to inhibit the formation of PGI2-like material by the vessel wall, it was lethal. Accordingly, local instillation of the drug was used and 
DISCUSSION
It has been suggested that the formation of PGI2 by the vessel wall may be an important protective mechanism against thrombosis (9) . The results of our experiments show that aspirin, when given in high doses, augments injury-induced thrombosis. This effect was not caused by changes in blood pH since these were slight and were also produced by sodium salicylate which was not thrombogenic. The findings do, however, support the concept that, when administered in large doses, aspirin potentiates thrombosis by inhibiting PGI2-like activity from the vessel wall. Furthermore, tranylcypromine augmented thrombosis and totally inhibited the production of PGI2-like activity in the assay system used.
The loss of thrombogenic effect of aspirin when the drug was administered at least 2 h before vessel damage suggests that the vessel wall cells were able to replace acetylated cyclo-oxygenase by synthesizing new enzyme. This is in contrast to the effect of aspirin the formation of PGI2-like activity by the vessel wall did not augment thrombosis, presumably because enough prostaglandin was synthesized to protect against injury-induced thrombosis.
The dose of aspirin required to augment thrombosis is much higher than the dose used clinically for management of thrombosis and the dose required to inhibit platelet prostaglandin synthesis. This is consistent with the report by Baenziger et al. in which it was demonstrated that much higher concentrations of aspirin were required to inhibit prostaglandin synthesis by cultured vessel wall smooth muscle cells than to inhibit prostaglandin synthesis in platelets (4). It is unlikely, therefore, that aspirin would be thrombogenic when used in therapeutic doses, however, our findings raise the possibility that other inhibitors of prostaglandin synthesis which have a greater effect on the vessel wall could potentiate thrombosis.
